The Effect of Ketamine on Sleep Quality in Patients Undergoing Colonoscopy

NCT ID: NCT06498869

Last Updated: 2024-10-09

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 178 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-07-30
• Study Completion Date: 2024-10-06

Brief Summary

Sedation typically begins with 2 mg of midazolam (0.025-0.1 mg/kg), followed by propofol given initially at 0.5-1.0 mg/kg bolus doses, with additional 0.25-0.5 mg/kg boluses as needed every 1-3 minutes to maintain sedation. Depending on clinical judgment, ketamine may be added to minimize propofol doses due to its minimal respiratory depression effects, administered at 0.25-0.50 mg/kg.

In the study protocol, participants undergo comprehensive assessments using the Pittsburgh Sleep Quality Index, Hospital Anxiety and Depression Scale, Numeric Rating Scale for Sleep Quality, and Richards Campbell Sleep Questionnaire on the procedure day, conducted in person.

Participants are randomized into two groups: one receiving midazolam and propofol (control group), and the other receiving ketamine in addition to midazolam and propofol.

Procedure duration and medication doses are meticulously recorded. Post-procedure, patients with a Modified Aldrete Score of 10 are transferred to the recovery unit. Participant data are documented, with follow-up conducted via phone 7 days post-procedure. Participants are reassessed using the aforementioned scales after the procedure, concluding the initial follow-up. The effects of ketamine on sleep quality will be evaluated by comparing the values of the mentioned scales before and after the procedure.

Detailed Description

During colonoscopy procedures, routine procedural sedation and analgesia are typically administered due to expected severe discomfort and pain. Sedation is administered by anesthesiologists using various medications according to established clinical guidelines, such as those outlined by the Turkish Society of Anesthesiology and Reanimation. Typically, an initial dose of 2 mg of midazolam (0.025-0.1 mg/kg) is administered, followed by propofol. Propofol is initially given at a bolus dose of 0.5-1.0 mg/kg, followed by additional bolus doses of 0.25-0.5 mg/kg at intervals of 1-3 minutes as required to achieve and maintain sedation. Depending on clinical judgment, some clinicians may supplement with ketamine, known for its minimal respiratory depression effects, to reduce propofol dosage. Ketamine is administered at doses of 0.25-0.50 mg/kg for this purpose. All medications are administered intravenously, aiming for a moderate sedation scale of 1-3 (TARD Non-operating Room Anesthesia Practice Guidelines, March 2022, page 17).

In the study protocol, participants will undergo the following procedures based on these guidelines.

Participants who consent to participate in the study will undergo assessment using the Pittsburgh Sleep Quality Index, Hospital Anxiety and Depression Scale, Numeric Rating Scale for Sleep Quality, and Richards Campbell Sleep Questionnaire on the day of the procedure. This assessment will be conducted in person.

Participants will be randomized into two groups. One group will receive midazolam and propofol, constituting the control group. The other group will receive ketamine in addition to midazolam and propofol during the procedure.

The duration of the procedure and total medication doses will be documented. After the procedure, patients achieving a Modified Aldrete Score of 10 will be discharged to the recovery unit (TARD Non-operating Room Anesthesia Practice Guidelines, March 2022, page 17).

Data on participants will be recorded, and they will be contacted by phone 7 days post-procedure.

Participants will undergo reassessment using the Pittsburgh Sleep Quality Index, Hospital Anxiety and Depression Scale, Numeric Rating Scale for Sleep Quality, and Richards Campbell Sleep Questionnaire scales after the procedure.

Following this assessment, participant follow-up will conclude. The effects of ketamine on sleep quality will be evaluated by comparing the values of the mentioned scales before and after the procedure.

Participants will be randomized into the Ketamine Group and Control Group in a 1:1 ratio. Randomization will be conducted using computer software by an independent researcher (AY). Randomization will be securely stored in sealed envelopes. An independent researcher (AŞ) will open the envelope 30 minutes prior to the procedure. The researcher administering anesthesia and the researcher conducting participant follow-ups and assessments (BG) will remain blinded to each other. Participants and the researcher assessing sleep quality (BG) will be unaware of the treatment administered to participants. The study is designed as a double-blind trial.

Conditions

Sleep

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: OTHER
• Blinding Strategy: DOUBLE

Study Groups

Ketamine Group

This group will receive ketamine (0.25-0.50 mg/kg) in addition to midazolam and propofol during the colonoscopy procedure

Group Type: ACTIVE_COMPARATOR

Ketamine Hcl 50Mg/Ml Inj

Intervention Type: DRUG

This group will be administered ketamine (0.25-0.50 mg/kg)

Control Group

For this group, midazolam and propofol will be administered during the colonoscopy procedure. Ketamine will not be administered additionally.

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

Ketamine Hcl 50Mg/Ml Inj

This group will be administered ketamine (0.25-0.50 mg/kg)

Intervention Type: DRUG

Other Intervention Names

Ketalar, Registry Number: 690G0D6V8H, Unique ID D007649

Eligibility Criteria

Inclusion Criteria

• Patients who agree to participate in the study
• Patients undergoing colonoscopy procedures
• Patients classified as ASA 1-2
• Male and female patients aged 18-65 years

Exclusion Criteria

• Patients who decline to participate in the study
• Patients allergic to ketamine, propofol, and midazolam
• Patients with acute or chronic pain
• Patients diagnosed with psychiatric disorders
• Patients using antidepressants or sleep medications
• Patients with sleep disorders
• Patients with a history of oncological diseases
• Patients experiencing complications related to colonoscopy procedures
• Patients experiencing complications related to anesthesia administration
• Patients with a body mass index (BMI) >30 kg/m²
• Patients with cognitive impairment or communication issues
• Pregnant and postpartum patients
• Patients with sleep apnea syndrome
• Patients with uncontrolled hypertension (Blood Pressure >180/110 mmHg)

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Kocaeli City Hospital

OTHER_GOV

Sponsor Role: lead

Responsible Party

Bedirhan Günel

Principal Investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

BEDİRHAN GÜNEL

Role: PRINCIPAL_INVESTIGATOR

Kocaeli City Hospital

Locations

Kocaeli City Hospital

Kocaeli, Izmit, Turkey (Türkiye)

Countries

Turkey (Türkiye)

References

Yang Y, Zhang Y, Zhou G, Yang Z, Yan H, Zhang J. Efficacy of epidural esketamine on postoperative sleep quality after laparoscopic and robotic lower abdominal surgeries: a study protocol for randomised, double-blind, controlled trial. BMJ Open. 2024 Feb 27;14(2):e081589. doi: 10.1136/bmjopen-2023-081589.

Reference Type: BACKGROUND

PMID: 38417951 (View on PubMed)

Cui M, Xing T, Zhao A, Zheng L, Zhang X, Xue H, Wu Z, Wang F, Zhao P. Effects of intraoperative sodium oxybate infusion on post-operative sleep quality in patients undergoing gynecological laparoscopic surgery: A randomized clinical trial. J Clin Anesth. 2024 May;93:111349. doi: 10.1016/j.jclinane.2023.111349. Epub 2023 Dec 1.

Reference Type: BACKGROUND

PMID: 38039631 (View on PubMed)

Qiu Y, Hou H, Zhang J, Wang X, Wang L, Wu Y, Deng L. The effect of preoperative sleep quality on the target plasma concentration of propofol and postoperative sleep in patients undergoing painless gastroscopy. BMC Anesthesiol. 2023 Jan 7;23(1):9. doi: 10.1186/s12871-022-01957-2.

Reference Type: BACKGROUND

PMID: 36609213 (View on PubMed)

Other Identifiers

KSH-ANREA-BG-02

Identifier Type: -

Identifier Source: org_study_id